Biotech Eiger Can Sell Rare-Disease Drug For $46M In Ch. 11
By Ben Zigterman · April 23, 2024, 5:53 PM EDT
Insolvent biotechnology company Eiger BioPharmaceuticals Inc. received approval Tuesday at a hearing in Texas to sell its drug treatment for a rare genetic disorder to Sentynl Therapeutics, a subsidiary of Indian drugmaker Zydus...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login